Can I Take Melatonin with Low-Dose Naltrexone?

Can you take them at the same time?

The naltrexone label does not name melatonin as an interaction. It also states that formal studies of interactions with non-opioid medicines were not performed for the labeled product. [1] That is a reason to describe the actual information precisely, rather than claim that separate metabolic pathways prove the combination cannot interact.

A pharmacist or prescriber can review the actual LDN preparation and melatonin product. Include the dose in milligrams, timing and reason for each. For a compounded liquid, distinguish the concentration from the volume taken so that the daily dose is clear.

There is no validated melatonin-LDN spacing schedule. Waiting an hour is not known to improve efficacy or reduce side effects. If a clinician changes the timing, the useful outcome is whether sleep and daytime function improve, not whether an arbitrary gap has been achieved.

What counts as low-dose naltrexone?

LDN describes lower oral doses used outside the standard labeled treatment regimens. Studies have used different amounts, including 4.5 mg and 6 mg daily in fibromyalgia. It is therefore inaccurate to define every low-dose regimen as exactly 1.5 to 4.5 mg.

Naltrexone is an opioid-receptor antagonist. Explanations involving endorphin rebound or immune-cell signaling are proposed mechanisms for some low-dose uses; they do not establish that bedtime is uniquely effective or that melatonin boosts the response.

The diagnosis and intended outcome should be explicit. A pain treatment and a sleep treatment can be assessed together without assuming they work through the same mechanism.

What do the fibromyalgia studies say about sleep?

The clinical results are more informative than a theory about nighttime endorphins:

These studies did not test adding melatonin. They support tracking pain and sleep as separate outcomes rather than promising that an LDN-melatonin combination will produce a larger anti-inflammatory or sleep benefit. [2-4]

The 2026 analysis is not an independent second group of patients. It reanalyzes outcomes from FINAL, which matters when counting the amount of clinical evidence.

If LDN seems to disrupt sleep

An early LDN pilot reported minor, transient insomnia and vivid dreams in some participants. [5] New dreams are not necessarily the same as poor sleep: someone may remember dreams more clearly while still waking refreshed, or may have repeated awakenings and impaired daytime function.

Record which pattern you experience and when it began. Starting melatonin at the same time as changing LDN can make it harder to identify which change mattered. When practical, the prescriber can assess one adjustment at a time.

Discuss timing, dose and formulation before repeatedly increasing a sleep supplement. Morning LDN is sometimes considered when evening dosing is troublesome, but there is no established melatonin-based rule that requires moving LDN to the morning. The decision should be tied to response and tolerability.

Melatonin needs its own medication review

A major example is fluvoxamine. A human study demonstrated substantially increased melatonin exposure when the two were combined. [6] That interaction involves fluvoxamine and melatonin; it should not be attributed to LDN or assumed to disappear by separating LDN from bedtime.

Product details also matter. Immediate-release and prolonged-release melatonin have different release patterns. A multi-ingredient sleep product may contain additional substances that need their own review. The serving size and amount per tablet, gummy or drop should be recorded accurately.

The National Center for Complementary and Integrative Health describes melatonin as a US dietary supplement, not as an unregulated product. It also notes possible daytime drowsiness and the need to consider existing medicines and individual circumstances. [7]

Glucose: interpret the actual experiment

An acute study in 21 healthy women tested melatonin 5 mg shortly before a glucose-tolerance test and found an impaired glucose response compared with placebo. [8] That finding concerns melatonin and the testing conditions; it does not demonstrate an LDN-melatonin interaction or establish that doses below 5 mg have no effect.

For someone with diabetes or prediabetes, discuss supplement timing and any unexpected glucose changes in the context of the existing care plan. A blanket instruction to add fasting-glucose tests for everyone taking LDN plus melatonin is not supported by that experiment.

There is also no basis for claiming that LDN reliably offsets melatonin's glucose effects. Separate proposed mechanisms cannot be combined into a prediction about an individual's blood sugar.

A practical review at follow-up

Pregnancy or pregnancy planning should be discussed for both products within the existing treatment review. Severe allergic symptoms such as swelling with difficulty breathing need urgent care. Marked sedation or significant high- or low-glucose symptoms in someone with diabetes also require timely assessment.

References